ReviewOncoTargets and therapy2019

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.

Niki Karachaliou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.